648 related articles for article (PubMed ID: 25493602)
1. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
[TBL] [Abstract][Full Text] [Related]
2. Medroxyprogesterone acetate levels among Kenyan women using depot medroxyprogesterone acetate in the FEM-PrEP trial.
Nanda K; Callahan R; Taylor D; Wang M; Agot K; Jenkins D; Van Damme L; Dorflinger L;
Contraception; 2016 Jul; 94(1):40-7. PubMed ID: 26972780
[TBL] [Abstract][Full Text] [Related]
3. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception.
Murnane PM; Heffron R; Ronald A; Bukusi EA; Donnell D; Mugo NR; Were E; Mujugira A; Kiarie J; Celum C; Baeten JM;
AIDS; 2014 Jul; 28(12):1825-30. PubMed ID: 24785951
[TBL] [Abstract][Full Text] [Related]
4. Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques.
Radzio J; Hanley K; Mitchell J; Ellis S; Deyounks F; Jenkins L; Heneine W; García-Lerma JG
J Acquir Immune Defic Syndr; 2014 Dec; 67(4):365-9. PubMed ID: 25202923
[TBL] [Abstract][Full Text] [Related]
5. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda.
Grabowski MK; Gray RH; Makumbi F; Kagaayi J; Redd AD; Kigozi G; Reynolds SJ; Nalugoda F; Lutalo T; Wawer MJ; Serwadda D; Quinn TC; Tobian AAR
Lancet Glob Health; 2015 Aug; 3(8):e478-e486. PubMed ID: 26094162
[TBL] [Abstract][Full Text] [Related]
6. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies.
Jain AK
Contraception; 2012 Dec; 86(6):645-52. PubMed ID: 22541635
[TBL] [Abstract][Full Text] [Related]
7. Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception.
Heffron R; Parikh UM; Penrose KJ; Mugo N; Donnell D; Celum C; Mellors JW; Baeten JM;
AIDS Behav; 2017 Jul; 21(7):2173-2179. PubMed ID: 27699594
[TBL] [Abstract][Full Text] [Related]
8. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial.
Murnane PM; Celum C; Mugo N; Campbell JD; Donnell D; Bukusi E; Mujugira A; Tappero J; Kahle EM; Thomas KK; Baeten JM;
AIDS; 2013 Aug; 27(13):2155-60. PubMed ID: 24384592
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate Use on HIV Pre-exposure Prophylaxis in Women.
Tarleton J; Chen BA; Meyn LA; Hendrix CW; Marzinke MA; Achilles SL
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):182-188. PubMed ID: 32568766
[TBL] [Abstract][Full Text] [Related]
11. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.
Noguchi LM; Richardson BA; Baeten JM; Hillier SL; Balkus JE; Chirenje ZM; Bunge K; Ramjee G; Nair G; Palanee-Phillips T; Selepe P; van der Straten A; Parikh UM; Gomez K; Piper JM; Watts DH; Marrazzo JM;
Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597
[TBL] [Abstract][Full Text] [Related]
12. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
[TBL] [Abstract][Full Text] [Related]
13. Depot Medroxyprogesterone Acetate Use Is Associated With Elevated Innate Immune Effector Molecules in Cervicovaginal Secretions of HIV-1-Uninfected Women.
Guthrie BL; Introini A; Roxby AC; Choi RY; Bosire R; Lohman-Payne B; Hirbod T; Farquhar C; Broliden K
J Acquir Immune Defic Syndr; 2015 May; 69(1):1-10. PubMed ID: 25622059
[TBL] [Abstract][Full Text] [Related]
14. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
[TBL] [Abstract][Full Text] [Related]
15. Responding to the ECHO trial results: modelling the potential impact of changing contraceptive method mix on HIV and reproductive health in South Africa.
Smith JA; Beacroft L; Abdullah F; Buthelezi B; Makua M; Morroni C; Ramjee G; Velasquez C; Hallett TB
J Int AIDS Soc; 2020 Oct; 23(10):e25620. PubMed ID: 33030312
[TBL] [Abstract][Full Text] [Related]
16. Increased Cervical CD4
Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
[TBL] [Abstract][Full Text] [Related]
17. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
19. A randomized clinical trial on the effects of progestin contraception in the genital tract of HIV-infected and uninfected women in Lilongwe, Malawi: Addressing evolving research priorities.
Kourtis AP; Haddad L; Tang J; Chinula L; Hurst S; Wiener J; Ellington S; Nelson JA; Corbett A; De Paris K; King CC; Hosseinipour M; Hoffman IF; Jamieson DJ
Contemp Clin Trials; 2017 Jan; 52():27-34. PubMed ID: 27836505
[TBL] [Abstract][Full Text] [Related]
20. Alignment of PrEP use and effective contraceptive use among East African women in HIV serodiscordant partnerships.
Ngure K; Velloza J; Patel RC; Mugo NR; Bukusi EA; Haberer JE; Odoyo J; Celum C; Baeten JM; Heffron R
Int J STD AIDS; 2020 Nov; 31(13):1263-1271. PubMed ID: 32998640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
